Henry B. Gonzalez Convention Centre December 6-10, 2022 Wednesday, December 14, 2022 The San Antonio Breast Cancer Symposium (SABCS) is an annual event cosponsored by the AACR and UT Health San Antonio’s Mays Cancer Center. The meeting hosts about 10,000 clinicians and scientists from all over the world and is the largest and most prestigious scientific gathering on breast cancer research. This international scientific symposium allows for the important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer. We are committed to meet the needs of breast cancer patients through high-quality and equal access to care to include prevention, early detection, and treatment. CCTG MAC.15 | SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Session: Oral General Session 1 Abstract: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007) Abstract #: GS1-01 Authors: Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K CCTG MAC.15 | SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer Session: Oral General Session 1 Abstract: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status Abstract #: GS1-04 Authors: Kang I, Forschmiedt JK, Loch MM, Barlow WE, Lew DL, Gralow JR, Meric-Bernstram F, Albain KS, Hayer DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Miao J, Tripathy D, Pusztai L, Hortobagyi GN, Kalinksy K, Henry NL. CCTG MAC.12 | ECOG PACCT-1 – Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial Session: Oral General Session 1 Abstract: Trial assigning individualized options for treatment (TAILORx): An Update Including 12-Year Event Rates Abstract #: GS1-05 Authors: Sparano J, Gray RJ, Makower D, Albain KS, Hayes DF, Geyer C, Dees E, Goetz MP, Olson JA, Lively TG, Badve S, Saphner T, Wagner LI, Whelan T, Kaklamani V, Sledge G. Not Trial-Specific Session: Poster Session 1 – Adjuvant Endocrine Therapy Abstract: Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis Abstract #: P1-02-01 Authors: Janni W, Untch M, Harbeck N, Gilgorov J, Jacot W, Chia SK, Boileau JF, Haftchenary S, Gupta R, Mishra N, Pathak P, Curigliano G CCTG MAC.15 | SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer. Session: Special Session Abstract: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score < / 25 randomized to endocrine therapy +/- chemotherapy: results from SWOG S1007 (RxPONDER) Abstract #: HER2-19 Authors: Spring LM, Barlow WE, Bardia A, Sharma P, Pusztai L, Hortobagyi GN, Kalinsky K. CCTG MA.9 | SWOG 8814: Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors Session: Poster Session 2 – Prognostic & Predictive Factors: Prognosis-Biomarkers of Natural History-Prog Factors-Clin Testing & Val Abstract: Computer analysis of nuclear morphology with multiple instance learning Predicts overall survival for node positive breast cancer patients from SWOG S8814: A blinded validation study Abstract #: P2-11-11 Authors: Shao D, Barlow WE, Li H, Lu C, Albain KS, Rae J, Hayes, DF, Godwin AK, Thompson AM, Madabhushi A, Puxztai L. CCTG MA.9 | SWOG 8814: Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors Session: Poster Session 2 – Prognostic & Predictive Factors: Prognosis-Biomarkers of Natural History-Prog Factors-Clin Testing & Val Abstract: Computerized measurements of nuclear morphology features, mitosis rate, and tubule formation from H&E images predicts disease-free survival in patients with HR+ & LN+ invasive breast cancer from SWOG S8814 Abstract #: P2-11-16 Authors: Chen Y, Barlow WE, Li H, Lu C, Janowczyk A, Corredor G, Ganesan S, Feldman M, Fu P, Gilmore H, Albain KSH, Pusztai L, Rae J, Hayes D, Godwin AK, Thompson AM, Madabhushi A. CCTG IND.236: A Phase IB and Open Label Phase II Study of CFI-402257 in Combination with Weekly Paclitaxel in Patients with Advanced/Metastatic HER2-Negative Breast Cancer Session: Poster Session 3 – Treatment: Therapeutic Strategies – New Drugs and Treatment Strategies Abstract: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC) Abstract #: P3-07-10 Authors: Bedard P, Mates M, Hilton J, Lavasseur N, Awan A, Srikanthan A, Cescon DW, Gelmon K, Robinson A, Dummond-Ivars N, Li I, Rastgou L, Edwards J, Hagerman L, Zhang S, Bray, M, Seymour L, Rushton M, Gaudreau PO. CCTG IND.239: A Phase II Study of CFI-400945 and Durvalumab in Patients with Advanced/ Metastatic Triple Negative Breast Cancer (TNBC) Session: Poster Session 3 – Treatment: Therapeutic Strategies – New Drugs and Treatment Strategies Abstract: CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC) Abstract #: P3-07-18 Authors: Hilton J, Cescon DW, Robinson A, Dhesy-Thind S, Taylor S, Ng TL, Rushton M, Savard MF, Muyot L, Reeves MC, Hagerman L, Lui H, Bray M, Tu D, Seymour L, Gaudreau PO. CCTG IND.237: A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer Session: Poster Session 3 – Treatment: Therapeutic Strategies – New Drugs and Treatment Strategies Abstract: A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237 Abstract #: P3-07-14 Authors: Cescon DW, Hilton J, Bedard P, Blachette P, Pezo RC, Bashir A, Kumar V, Ng TL, Awan A, Lott A, Raphael JA, Hagerman L, Bray M, Muyot L, Antras JF, Seymour L, Tu D, Gaudreau PO, Rushton M. CCTG MA.20: A Phase III Study of Regional Radiation Therapy in Early Breast Cancer Session: Poster Session 4 – Prognostic and Predictive Factors: Biomarkers Predicting Tx Response: Predictive Biomarkers - Other Abstract: Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional radiotherapy trial Abstract #: P4-02-16 Authors: Riaz N, Chen B, Bane A, Gao D, Stovgaard E. Kos Z, Leung S, Shenasa E, Parulekar W, Chambers S, Nielsen T, Whelan TJ. CCTG MA.40: A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER) Session: Poster Session 3 Ongoing Trials – Targeting PI3K/mTOR Abstract: CCTG MA40: Double-blind placebo controlled phase III trial of fulvestrant and ipatasertib for advanced her-2 negative and estrogen receptor positive (er+) breast cancer post first line cdk 4/6 and aromatase inhibitor therapy (finer) Abstract #: OT3-26-01 Authors: Chia SK, Cescon DW, Redfern AD, Rodin D, Simmons C, Ayoub JP, Ibrahim H, Rayson D, Rushton-Marovac M, Hay T, Gallinaro L, Chen B, Parulekar W. CCTG MAC.15 | SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Session: Poster Session 6; Detection and Diagnosis: Diagnostic Pathology Abstract: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status Abstract #: P6-05-06 Authors: Loch MM, Forschmiedt JK, Kang IM, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Barlow W, Tripathy D, Pusztai L, Hortobagyi GN, Kalinksy K. CCTG MA.38: Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer Session: Poster Session 5 – Prognostic and Predictive: Biomarkers Predicting Tx Response: For Targeted Therapies Abstract: Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial Abstract #: P5-02-27 Authors: McCartney A, Biagioni C, Chen B, Shepherd L, Gelmon K, Joy AA, Parulekar W, Bergqvist M, Migliaccio I, Leo A, Benelli M, Risi E, Moretti E, Luca L, Biganzoli L, Malorni L.
